Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
|Articles|March 1, 2017
Kerry
Advertisement
AmpliCHO CD Medium
AmpliCHO CD medium is a completely chemical chemically-defined medium that does not contain supplements. It is optimized for extended growth and enhanced recombinant protein production for CHO suspension cultures. AmpliCHO CD medium can be used as a basal medium, without anything added, or can have additional elements added based on the customer requirements.
Advertisement
Related to this article
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
In the Phase 2a INFORM-MS trial, Tiziana’s nasal foralumab reduced microglial activation on PET imaging at 50 µg in non-active secondary progressive MS, while the 100-µg dose showed no significant effect.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
Advertisement
Advertisement
Trending on BioPharm International
1
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
2
FDA Grants Accelerated Approval to Inovio DNA Immunotherapy for RRP
3
FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review
4
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
5